{
  "id": 6431855,
  "title": "Novel Target Combinations in Lung Squamous Cell Carcinoma proposed by the Emet AI Research Environment and supported by discovery stage experimentation",
  "url": "https://urgent.news/2026/09/09/novel-target-combinations-in-lung-squamous-cell-carcinoma-proposed-by",
  "topic": "ai",
  "section": "AI",
  "published": "2026-09-09T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.04.749404v1?rss=1"
  },
  "original_language": "en",
  "account": "Early drug discovery often struggles with identifying targets, especially in complex diseases such as lung squamous cell carcinoma (LUSC), which lacks a single dominant driver. Emet, an AI research environment, was developed to address this challenge by utilizing a biomedical knowledge graph of over 1.5 billion triples connected to over 100 specialized biological databases. Emet employs an Agentic Research Director that reasons across interconnected datasets to generate novel, mechanistically grounded therapeutic hypotheses for LUSC. The top-ranked hypotheses were two-target combinations rather than a single target. Four of the highest-ranked combinations were advanced to dose-matrix testing in NCI-H520 and SK-MES-1 cells. Two of these combinations produced synergistic effects, either exceeding the effects of the single agents or showing additive effects when tested on the cancer cells. These two combinations had not been previously evaluated in LUSC. Specifically, dual inhibition of CDC7 (TAK-931) and PKMYT1 (RP-6306) demonstrated statistically significant synergy in both cell lines, with the synergy strengthening over time. Additionally, dual inhibition of USP13 (spautin-1) and PI3K (alpelisib) produced an additive, cell-line-dependent effect, which was confirmed through immunoblotting. The immunochemical analysis revealed time-dependent depletion of MCL-1, c-Myc, and SOX-2 driven by the USP13 arm. Thus, Emet's agentic reasoning over multi-domain biomedical evidence successfully identified testable, mechanism-bearing combination hypotheses that withstood experimental scrutiny.",
  "summary": "Early drug discovery is frequently bottlenecked by target identification, a challenge that becomes particularly difficult in complex diseases driven by overlapping, redundant pathways rather than a single dominant driver. Lung squamous cell carcinoma (LUSC) is one such disease: mutationally complex, lacking a dominant actionable target, and marked by a long series of failed single-agent targeted…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}